Prehypertension: Is it relevant for nephrologists

Kidney International

Volumn 77, Issue 3, 2010, Pages 194-200

  Kalaitzidis, Rigas G ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Hypertension; Kidney; Nephropathy; Prevention

Indexed keywords

CANDESARTAN HEXETIL; CREATININE; ENALAPRIL; INDAPAMIDE PLUS PERINDOPRIL; LOSARTAN; NISOLDIPINE; PLACEBO;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MICROALBUMINURIA; NEPHROLOGIST; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 74449087028     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.439     Document Type: Short Survey

References (49)

1. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
2. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18.
3. Hsu CY, McCulloch CE, Darbinian J et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005; 165: 923-928.
4. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
5. Gu Q, Burt VL, Paulose-Ram R et al. High blood pressure and cardiovascular disease mortality risk among U.S. adults: the third National Health and Nutrition Examination Survey mortality follow-up study. Ann Epidemiol 2008; 18: 302-309.
6. Vasan RS, Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-1010. (Pubitemid 34252058)
7. Camici GG, Sudano I, Noll G et al. Molecular pathways of aging and hypertension. Curr Opin Nephrol Hypertens 2009; 18: 134-137.
8. Cordero A, Laclaustra M, Leon M et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy. Am J Hypertens 2006; 19: 189-196.
9. Liu K, Ruth KJ, Flack JM et al. Blood pressure in young blacks and whites: relevance of obesity and lifestyle factors in determining differences. The CARDIA Study. Circulation 1996; 93: 60-66.
10. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004; 164: 2126-2134.
11. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174.
12. Lee JE, Kim YG, Choi YH et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 2006; 47: 962-967.
13. Greenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Intern Med 2004; 164: 2113-2118.
14. Knight SF, Imig JD. Obesity, insulin resistance, and renal function. Microcirculation 2007; 14: 349-362.
15. Bonnet F, Deprele C, Sassolas A et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720-727.
16. Lin SJ, Lee KT, Lin KC et al. Prevalence of prehypertension and associated risk factors in a rural Taiwanese adult population. Int J Cardiol 2009, published online pii:S0167-5273(09)00081-83 doi:10.1016/j.ijcard.2009.01. 045.
17. Mainous III AG, Everett CJ, Liszka H et al. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol 2004; 94: 1496-1500.
18. Norton GR, Maseko M, Libhaber E et al. Is prehypertension an independent predictor of target organ changes in young-to-middle-aged persons of African descent? J Hypertens 2008; 26: 2279-2287.
19. Chrysohoou C, Pitsavos C, Panagiotakos DB et al. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA study. Am J Hypertens 2004; 17: 568-573. (Pubitemid 38844982)
20. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med 2006; 26: 635-653.
21. Solbu MD, Jenssen TG, Eriksen BO et al. Changes in insulin sensitivity, renal function, and markers of endothelial dysfunction in hypertension-the impact of microalbuminuria: a 13-year follow-up study. Metabolism 2009; 58: 408-415.
22. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
23. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol 2006; 1: 229-235.
24. Kalaitzidis RG, Bakris GL. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens 2009; 18: 386-391.
25. Csiszar A, Wang M, Lakatta EG et al. Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol 2008; 105: 1333-1341.
26. Drukteinis JS, Roman MJ, Fabsitz RR et al. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart study. Circulation 2007; 115: 221-227.
27. Ilyas B, Dhaun N, Markie D et al. Renal function is associated with arterial stiffness and predicts outcome in patients with coronary artery disease. QJM 2009; 102: 183-191.
28. Khosla N, Kalaitzidis R, Bakris GL. The kidney, hypertension, and remaining challenges. Med Clin North Am 2009; 93: 697-715, Table of Contents.
29. Schaeffner ES, Kurth T, Bowman TS et al. Blood pressure measures and risk of chronic kidney disease in men. Nephrol Dial Transplant 2008; 23: 1246-1251.
30. Reynolds K, Gu D, Muntner P et al. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. J Am Soc Nephrol 2007; 18: 1928-1935.
31. Obermayr RP, Temml C, Knechtelsdorfer M et al. Predictors of new-onset decline in kidney function in a general middle-European population. Nephrol Dial Transplant 2008; 23: 1265-1273.
32. Haroun MK, Jaar BG, Hoffman SC et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003; 14: 2934-2941.
33. Kalaitzidis R, Li S, Wang C et al. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009; 53: S22-S31.
34. Shankar A, Klein R, Klein BE et al. Relationship between low-normal blood pressure and kidney disease in type 1 diabetes. Hypertension 2007; 49: 48-54.
35. Hansen KW, Poulsen PL, Ebbehoj E et al. What is hypertension in diabetes? Ambulatory blood pressure in 137 normotensive and normoalbuminuric type 1 diabetic patients. Diabet Med 2001; 18: 370-373.
36. Thomas W, Shen Y, Molitch ME et al. Rise in albuminuria and blood pressure in patients who progressed to diabetic nephropathy in the Diabetes Control and Complications Trial. J Am Soc Nephrol 2001; 12: 333-340.
37. Osawa Y, Narita I, Imai N et al. Determination of optimal blood pressure for patients with IgA nephropathy based on renal histology. Hypertens Res 2001; 24: 89-92.
38. Ninomiya T, Kubo M, Doi Y et al. Prehypertension increases the risk for renal arteriosclerosis in autopsies: the Hisayama study. J Am Soc Nephrol 2007; 18: 2135-2142.
39. Nathan DM, Zinman B, Cleary PA et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169: 1307-1316.
40. McDonough CW, Bostrom MA, Lu L et al. Genetic analysis of diabetic nephropathy on chromosome 18 in African Americans: linkage analysis and dense SNP mapping. Hum Genet 2009, published online doi: 10.1007/ s00439-009-0732-738
41. Elmer PJ, Obarzanek E, Vollmer WM et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006; 144: 485-495.
42. Xu KT, Ragain RM. Effects of weight status on the recommendations of and adherence to lifestyle modifications among hypertensive adults. J Hum Hypertens 2005; 19: 365-371.
43. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Am J Nephrol 2009; 30: 95-98.
44. Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.
45. Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
46. Marre M, Leblanc H, Suarez L et al. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J (Clin Res Ed) 1987; 294: 1448-1452.
47. Schrier RW, Estacio RO, Esler A et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097.
48. de Galan BE, Perkovic V, Ninomiya T et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883-892.
49. Shimizu A, Takei T, Uchida K et al. Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res 2008; 31: 1711-1717.